15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Ultragenyx, 14 rate it Buy or better, 6 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $16.00 to $90.00 (about 5.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $36.63 sits 146% above the current $14.88. The rating mix has stayed broadly stable, with Buy-side ratings easing from 15 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.55 next quarter toward $0.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Moderate Buy
Strong Buy00%
Buy1470%
Hold630%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Ultragenyx.
As of Sep, 14 of 20 firms rate RARE a Buy (6 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RARE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.55
Range $-1.08 – $0.78 · 4 analysts · -57% YoY
Next period, 4 analysts expect Ultragenyx to earn $-0.55 a share (range $-1.08 – $0.78), versus $-1.29 a year earlier. Full-year consensus is $-3.85, growing to $0.67 the year after.
REVENUE · NEXT QUARTER
$227.9M
Range $191.4M – $360.9M · 4 analysts · +10% YoY
Revenue is expected to reach $227.9M (range $191.4M – $360.9M), +10.1% year-over-year. Full-year consensus is $762.6M, rising to $1.0B next year.
Top analysts covering Ultragenyx
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RARE.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$19.00+27.7% to target
Overall win rate
55%
+ Follow
#2
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Buy
$74.00+397.3% to target
Overall win rate
64%
+ Follow
#3
Laura Chico
Wedbush · Rank #74
Hold
$23.00+54.6% to target
Overall win rate
44%
+ Follow
#4
Anupam Rama
JP Morgan · Rank #75
Hold
$36.00+141.9% to target
Overall win rate
51%
+ Follow
#5
Joel Beatty
Baird · Rank #80
Hold
$16.00+7.5% to target
Overall win rate
48%
+ Follow
RARE stock forecast FAQ
What is RARE's average 12-month price target?+
The 19 analysts with a live target average $36.63 for Ultragenyx over the next 12 months, ranging from a $90.00 high to a $16.00 low.
Is RARE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 20 analyst ratings, 14 are Buy or Strong Buy, 6 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RARE?+
The Street-high target is $90.00 (Truist Securities), and the Street-low is $16.00 (Evercore ISI Group). The average of all 19 active targets is $36.63.
How many Wall Street analysts cover RARE?+
20 analysts have an active rating on Ultragenyx, and 19 firms carry a live 12-month price target.
Who is the most accurate analyst covering RARE?+
Among analysts who currently cover RARE, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $19.00 target.
What is Ultragenyx's projected EPS for next quarter?+
The consensus estimate is $-0.55 per share (range $-1.08 – $0.78) across 4 analysts. Full-year EPS is projected at $-3.85, rising to $0.67 the following year.
How much revenue is Ultragenyx expected to report next quarter?+
Consensus revenue is $227.9M (range $191.4M – $360.9M). Full-year revenue is projected at $762.6M, growing to $1.0B next year.
Have analysts been upgrading or downgrading RARE lately?+
As of Sep, 14 of 20 firms rate RARE a Buy (6 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RARE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
